Evidence map›Paper›PMID 36960104›Full record

ArticleVaccine: X2023

Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history.

Kenji Ota, Satoshi Murakami, Kaori Ishihara, Daisuke Sasaki, Tetsuya Usui, Fujiko Mitsumoto-Kaseida, Kei Sakamoto, Kosuke Kosai, Hiroo Hasegawa, Takahiro Takazono and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kenji OtaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Satoshi MurakamiAbbott Japan LLC, Tokyo, Japan.
Kaori IshiharaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Daisuke SasakiDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Tetsuya UsuiDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Fujiko Mitsumoto-KaseidaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Kei SakamotoDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Kosuke KosaiDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Hiroo HasegawaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Takahiro TakazonoDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Akitsugu FurumotoJuzenkai Hospital, Nagasaki, Japan.
Norichika AsohJuzenkai Hospital, Nagasaki, Japan.
Hiroyuki YoshimineInoue Hospital, Nagasaki, Japan.
Toyomitsu SawaiNagasaki Harbor Medical Center, Nagasaki, Japan.
Masanari OnizukaNagasaki Kita Tokushukai Hospital, Nagasaki, Japan.
Noriaki MakimotoTagami Hospital, Nagasaki, Japan.
Koichi IzumikawaInfection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Shigeru KohnoNagasaki University, Nagasaki, Japan.
Katsunori YanagiharaDepartment of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The IgG antibody titer against SARS-CoV-2 receptor binding protein (RBD) after mRNA vaccine were compared between those with and without previous infection (PI) for up to 48 weeks. Though sustained higher IgG-RBD were observed in the PI group after two doses of vaccines, both groups benefited from the booster shots of the third vaccine. This data supports the necessity of the booster shots to those with PI.

Indexed as

Booster shotPrevious infection historySARS-CoV-2 vaccineSerological response

Identifiers

PMID36960104
PMCPMC10022459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.